Nalbuphine Administration Protocol in the Emergency Department
Your current ER practice of diluting nalbuphine (Nalbin) with Gravinate to 10 mL and administering 3 mL IV is not supported by standard guidelines and should be modified to follow FDA-approved protocols for safe and effective administration.
Recommended Administration Protocol
Based on FDA labeling, nalbuphine should be administered according to the following parameters 1:
Standard Dosing
- Initial dose: 10 mg for a 70 kg individual
- Routes: Subcutaneous, intramuscular, or intravenous
- Frequency: Every 3-6 hours as necessary
- Maximum single dose: 20 mg (in non-tolerant individuals)
- Maximum daily dose: 160 mg
Proper Dilution and Administration
For IV administration, nalbuphine does NOT require routine dilution 1. The medication comes as a ready-to-use sterile solution at 20 mg/mL concentration 1.
If you choose to dilute for slower administration:
- Use normal saline or compatible IV solution
- Administer slowly over several minutes
- Monitor for respiratory depression
Critical Safety Considerations
Your current 3 mL dose from a 10 mL dilution is problematic because:
- The final concentration and actual nalbuphine dose delivered is unclear
- Gravinate (dimenhydrinate) compatibility with nalbuphine is not established
- Guidelines emphasize checking physicochemical compatibility when mixing opioids with other drugs parenterally 2
Alternative Evidence-Based Approach
Recent research supports co-administration strategies:
For patients prone to injection pain 3:
- Mix equal volumes of nalbuphine (1 mL = 10 mg) with lidocaine (1 mL = 20 mg)
- This undiluted combination significantly reduces injection pain (2.5% vs 30% incidence)
- Administer at 0.33 mL/second
Standard practice should be:
- Draw up the appropriate dose based on patient weight (typically 0.1-0.2 mg/kg) 4
- Administer undiluted IV push slowly, OR
- If dilution preferred, use normal saline only (not Gravinate)
- Have naloxone immediately available 2
Common Pitfalls to Avoid
- Do not mix nalbuphine with antiemetics without verified compatibility data
- Do not use arbitrary dilution volumes that obscure actual dosing
- Do not administer rapidly - this increases injection pain and adverse effects
- Always calculate dose by patient weight, not fixed volumes
Monitoring Requirements
After administration 1:
- Monitor respiratory rate closely for first 24-72 hours
- Keep naloxone, resuscitation equipment, and oxygen readily available
- Watch for respiratory depression (rate <8/min requires intervention)
- Assess pain relief and titrate subsequent doses accordingly
Bottom line: Abandon the current Gravinate dilution practice. Use nalbuphine undiluted or diluted only with normal saline, dose by patient weight (0.1-0.2 mg/kg), and administer slowly IV with appropriate monitoring.